Due to the negative regulation of Lynx1 on nAChR activity, especially through the inhibition of GABAergic-mediated mucin upregulation, Lynx1-mimetics have been suggested as potential treatment options in asthma and COPD [105]. This evidence concerns the gene LYNX1 and chronic obstructive pulmonary disease.